Stockreport

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

ASLAN Pharmaceuticals Limited - American Depositary Shares  (ASLN) 
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MA [Read more]